We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC

Delisted

BCLI was delisted on the 17th of July, 2025.

76 hedge funds and large institutions have $70M invested in BRAINSTORM CELL THERAPUTC in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

313% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 8

307% more capital invested

Capital invested by funds: $17.2M → $70M (+$52.8M)

67% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 12

49% more funds holding

Funds holding: 5176 (+25)

0.51% more ownership

Funds ownership: 0.9%1.41% (+0.51%)

76% less call options, than puts

Call options by funds: $9.36M | Put options by funds: $38.3M

Holders
76
Holders Change
+25
Holders Change %
+49.02%
% of All Funds
1.56%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
33
Increased
20
Reduced
12
Closed
8
Calls
$9.36M
Puts
$38.3M
Net Calls
-$28.9M
Net Calls Change
-$29.2M

BCLI Hedge Fund Activity: Q2 2020 in Review

76 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2020, worth a combined $70M — up 307% from $17.2M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new BCLI positions and 8 closed out — a net gain of 25 holders — while 20 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $10.6M. The largest seller was Renaissance Technologies, cutting an estimated $3.13M.

  • 76 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2020, up from 51 in Q1 2020.
  • Funds reported $70M of BRAINSTORM CELL THERAPUTC stock for Q2 2020, up 307% quarter-over-quarter.
  • 33 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2020 and 8 closed out, a net change of +25 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2020 was BlackRock, an estimated $10.6M added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q2 2020 was Renaissance Technologies, an estimated $3.13M sold.

Based on aggregated 13F filings for Q2 2020.